Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2021 | Bi-specific antibodies in HER2+ gastric cancer

Hyun C. Chung • 13 Jan 2021
ASCO GI 2021
Gastric Cancer Gastrointestinal Cancer Antibodies

Hyun C. Chung, MD, PhD, Yonsei Cancer Center, Seoul, Republic of Korea, provides an overview of ongoing studies in patients with HER2+ gastric cancer, including the use of novel immunotherapy and bi-specific antibodies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Hyun C. Chung

1:04
PANTHERA: pembrolizumab, trastuzumab, and chemotherapy in HER2+ advanced gastric cancer
Hyun C. Chung • 13 Jan 2021
3:03
Promising results from the gastric cancer cohort of LEAP-005
Hyun C. Chung • 13 Jan 2021

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals